Monitor upcoming clinical data readouts: CTX310 Phase 1b at AHA (Nov 9) and zugo-cel SSc data at ACR (Nov 8) could drive near-term volatility. CASGEVY revenue trajectory remains strong but the collaboration accounting structure limits direct top-line benefit. Cash runway of $2.3B provides multi-year visibility.
Price Chart
Executive Summary
CRISPR Therapeutics reported Q3 2026 total revenue of $12.7M (vs $16.6M consensus), driven by $12.3M in collaboration revenue from CASGEVY, which generated $99M in gross sales (up 30% QoQ and ~6x YoY). The company highlighted FDA RMAT designations for CTX310, completion of CTX611 Phase 2 enrollment, and upcoming clinical data readouts.
Key Financial Metrics
Key Facts
- CASGEVY revenue of $99M in Q3 2026, up 30% quarter-over-quarter and nearly 6x Q3 2025
- Total revenue of $12.7M (collaboration revenue $12.3M + grant revenue $0.3M) vs consensus $16.6M
- Cash, cash equivalents and marketable securities of $2,276.6M as of Sep 30, 2026
- FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C
- Completed enrollment in Phase 2 trial of CTX611 in total knee arthroplasty
- Phase 1b data for CTX310 at AHA Scientific Sessions Nov 9; Phase 1 data for zugo-cel in SSc at ACR Convergence Nov 8
- Appointed Siva Sakhamuri as CTO and A.J. Silver as CFO
Financial Impact
Revenue miss of ~$3.9M vs consensus; EPS miss of $0.09; CASGEVY gross revenue growth trajectory positive but not directly flowing to CRSP's top line due to 60/40 profit share with Vertex
Risk Factors
- Revenue and EPS missed consensus estimates
- Net loss widened year-over-year despite higher CASGEVY revenue
- R&D expenses increased 22% YoY to $71.9M, plus $11.7M in acquired in-process R&D milestone
- Shareholders' equity declined from $1.92B to $1.65B since Dec 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-443644 |
| Document: crsp-20261102.htm | 0001193125-26-443644 |
| Document: 0001193125-26-443644-index-headers.html | 0001193125-26-443644 |
| Document: 0001193125-26-443644-index.html | 0001193125-26-443644 |
| Document: 0001193125-26-443644.txt | 0001193125-26-443644 |
| 8-K Data (Synthetic) | 0001193125-26-443644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 8, 2026 today | Press Release | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 6, 2026 1d ago | 144 | $48.98 | awaiting T+20 | awaiting T+20 | $50.07 (+2.23%) |
Nov 2, 2026 5d ago | 3 | $49.99 | awaiting T+20 | awaiting T+20 | $50.07 (+0.16%) |
Nov 2, 2026 5d ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 2, 2026 5d ago | Press Release | $49.99 | awaiting T+20 | awaiting T+20 | $50.07 (+0.16%) |
Oct 20, 2026 18d ago | Insider Cluster | $50.50 | awaiting T+20 | awaiting T+20 | $50.07 (+0.85%) |
Oct 19, 2026 19d ago | 8-K | $49.88 | awaiting T+20 | awaiting T+20 | $50.07 (+0.38%) |
Oct 16, 2026 22d ago | Insider Cluster | $50.04 | awaiting T+20 | awaiting T+20 | $50.07 (+0.06%) |
Oct 16, 2026 22d ago | Insider Cluster | $50.04 | awaiting T+20 | awaiting T+20 | $50.07 (−0.06%) |
Oct 15, 2026 23d ago | Insider Cluster | $49.25 | awaiting T+20 | awaiting T+20 | $50.07 (+1.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers